Your browser doesn't support javascript.
loading
Short-Term Efficacy and Safety of Torasemide and Furosemide in 366 Dogs with Degenerative Mitral Valve Disease: The TEST Study.
Chetboul, V; Pouchelon, J-L; Menard, J; Blanc, J; Desquilbet, L; Petit, A; Rougier, S; Lucats, L; Woehrle, F.
Afiliación
  • Chetboul V; Alfort Cardiology Unit, Université Paris-Est, Ecole Nationale Vétérinaire d'Alfort, Maisons-Alfort Cedex, France.
  • Pouchelon JL; INSERM U955, Equipe 03, Créteil Cedex, France.
  • Menard J; Alfort Cardiology Unit, Université Paris-Est, Ecole Nationale Vétérinaire d'Alfort, Maisons-Alfort Cedex, France.
  • Blanc J; INSERM U955, Equipe 03, Créteil Cedex, France.
  • Desquilbet L; Vetoquinol SA, Paris, France.
  • Petit A; Vetoquinol SA, Lure, France.
  • Rougier S; Department of Biostatistics and Clinical Epidemiology, Université Paris-Est, Ecole Nationale Vétérinaire d'Alfort, Maisons-Alfort Cedex, France.
  • Lucats L; Alfort Cardiology Unit, Université Paris-Est, Ecole Nationale Vétérinaire d'Alfort, Maisons-Alfort Cedex, France.
  • Woehrle F; Vetoquinol SA, Lure, France.
J Vet Intern Med ; 31(6): 1629-1642, 2017 Nov.
Article en En | MEDLINE | ID: mdl-28975664
BACKGROUND: Furosemide is the only loop diuretic recommended by the ACVIM consensus guidelines for treatment of congestive heart failure (CHF) in dogs related to degenerative mitral valve disease (DMVD). Torasemide is another potent loop diuretic with a longer half-life and a higher bioavailability. OBJECTIVES: (1) To demonstrate that torasemide given once a day (q24h) is noninferior to furosemide given twice a day (q12h) for treating dogs with CHF; (2) and to compare the effect of the 2 drugs on the time to reach a composite cardiac endpoint "spontaneous cardiac death, euthanasia due to heart failure or CHF class worsening." ANIMALS: A total of 366 dogs with CHF attributable to DMVD. METHODS: Analysis of 2 prospective randomized single-blinded reference-controlled trials was performed. Dogs orally received either torasemide q24h (n = 180) or furosemide q12h (n = 186) in addition to standard CHF therapy over 3 months. The primary efficacy criterion was the percentage of dogs with treatment success assessed in each study. The time to reach the composite cardiac endpoint was used as secondary criterion in the overall population. RESULTS: Torasemide was noninferior to furosemide (Ptorasemide  - Pfurosemide  = +7%; 95% CI [-8%; +22%] and Ptorasemide  - Pfurosemide  = +1%; 95% CI [-12%; +14%], respectively, in Study 1 and Study 2). Torasemide (median dose = 0.24 mg/kg/d q24h; range = 0.10-0.69 mg/kg/d) was associated with a 2-fold reduction in the risk of reaching the composite cardiac endpoint (adjusted HR = 0.47; 95% CI = 0.27-0.82; P = 0.0077) as compared with furosemide (median dose = 1.39 mg/kg q12h; range = 0.70-6.30 mg/kg q12h). CONCLUSIONS AND CLINICAL IMPORTANCE: Torasemide q24h is an effective oral diuretic in dogs with CHF.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Sulfonamidas / Diuréticos / Furosemida / Insuficiencia Cardíaca / Enfermedades de las Válvulas Cardíacas Tipo de estudio: Guideline / Observational_studies / Risk_factors_studies Límite: Animals Idioma: En Revista: J Vet Intern Med Asunto de la revista: MEDICINA INTERNA / MEDICINA VETERINARIA Año: 2017 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Sulfonamidas / Diuréticos / Furosemida / Insuficiencia Cardíaca / Enfermedades de las Válvulas Cardíacas Tipo de estudio: Guideline / Observational_studies / Risk_factors_studies Límite: Animals Idioma: En Revista: J Vet Intern Med Asunto de la revista: MEDICINA INTERNA / MEDICINA VETERINARIA Año: 2017 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Estados Unidos